Protalix BioTherapeutics (PLX) Asset Utilization Ratio (2011 - 2026)

Protalix BioTherapeutics' Asset Utilization Ratio history runs 15 years deep, the most recent figure standing at 0.83 for Q1 2026.

• On a quarterly basis, Asset Utilization Ratio rose 1.94% year-over-year to 0.83 in Q1 2026; TTM through Mar 2026 was 0.83, a 1.94% increase from a year earlier, with the FY2025 full-year figure at 0.68, changed 0.1% from the prior year.
• Asset Utilization Ratio climbed to 0.83 in Q1 2026 per PLX's latest filing, from 0.64 in the prior quarter.
• Across five years, Asset Utilization Ratio topped out at 0.87 in Q2 2023 and bottomed at 0.42 in Q2 2024.
• The 5-year median for Asset Utilization Ratio is 0.76 (2023), against an average of 0.73.
• Across the five-year window, Asset Utilization Ratio slumped 51.8% in 2024 and soared 93.76% in 2025, its largest moves.
• Year by year, Asset Utilization Ratio stood at 0.85 in 2022, then fell by 10.08% to 0.76 in 2023, then advanced by 3.9% to 0.79 in 2024, then dropped by 19.01% to 0.64 in 2025, then gained by 29.08% to 0.83 in 2026.
• Per Business Quant, the three latest PLX Asset Utilization Ratio figures stand at 0.83 (Q1 2026), 0.64 (Q4 2025), and 0.77 (Q3 2025).